source
- Third Rock partner’s brain cancer diagnosis highlights personal impact of biotech drug developmentJigar Raythatha, a partner at Third Rock Ventures, was diagnosed with a rare form of brain cancer in 2023 after a routine MRI. On the same day his diagnosis was confirmed, Servier announced posit…
- BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapyBioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…